Low-risk Genes and Multi-organ Cancer Risk in the Polish Population by Tadeusz Dębniak et al.
Hereditary Cancer in Clinical Practice 2006; 4(1)52
Hereditary Cancer in Clinical Practice 2006; 4(1) pp. 52-55
Low-risk Genes and Multi-organ Cancer Risk in the Polish Population
Tadeusz Dêbniak, Cezary Cybulski, Grzegorz Kurzawski, Bohdan Górski, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald,
Janina Suchy, Bart³omiej Masojæ, Marek Mierzejewski, Marcin Lener, Urszula Teodorczyk, Krzysztof Mêdrek, El¿bieta Z³owocka,
Ewa Grabowska-K³ujszo, Katarzyna Nej-Wo³osiak, Anna Szymañska, Jolanta Szymañska-Pasternak, Joanna Matyjasik, Thierry
van de Wetering, Anna Jakubowska, Oleg Oszurek, Aleksandra To³oczko-Grabarek, Jennifer Castaneda, Rodney Scott, Steven
A. Narod, Jan Lubiñski
International Hereditary Cancer Center, Szczecin, Poland
Key words:  CDKN24,  CHEK2,  NOD2,  cancer  r i sk
Cor re spond ing  au thor :  Tadeusz  Dêbn iak ,   In te rna t iona l  Hered i ta ry  Cance r  Cen te r,  Pomeran ian  Med i ca l  Un ive r i s t y,  
u l .  Po³abska 4,  70-115 Szczec in,  Poland; e -mai l:  debniak@wp.pl
Submit ted:  10 December 2005
Accepted:  10 January 2006
There is continuing interest in identifying low-
penetrance genes which are associated with increased
susceptibility to common types of cancer. There are
several approaches to this problem, including the use
of chip-based single nucleotide polymorphism (SNP)
arrays to interrogate a large number of genes
simultaneously and pre-selecting candidate genes of
interest. Candidate genes for cancers of a particular
site may be selected because they are known to
predispose to malignancies of other organs, or because
they are mutated somatically in the cells from the
cancer of interest. It is possible that missense variants
of genes for which truncating mutations are clearly
pathogenic may also be deleterious, but with reduced
penetrance. In this situation the association may be
overlooked unless large numbers of cancers are
studied. 
In our centre we performed population-based
studies of common variants of three genes: a tumour-
suppressor gene CDKN2A (OMIM 600160), NOD2
(OMIM 605956) involved in the chronic inflammation
process, and CHEK2 (OMIM 604373) participating in
the DNA damage response.
To determine whether CDKN2A common variant
A148T may be associated with an increased risk of
malignancies at different sites of origin we genotyped
a series of 8,263 unselected cancer cases and
compared the frequency of the change observed in this
population to 3,000 controls in Poland. To establish
the range of cancer types associated with three CHEK2
mutations (VS2+1G → A, 1100delC, and I157T) we
genotyped 4,008 unselected cases of cancer and
4,000 controls in Poland. In order to define the range
of cancer phenotypes associated with the NOD2
3020insC mutation we examined 2,604 unselected
invasive cancers of 12 different types and 1,910
controls from Poland.
Results 
We showed an association between CDKN2A
common variant and increased risk of malignant
melanoma (OR=2.1), cancers of breast (under 50y,
OR=1.5), lung (OR=2.0) and colon (OR=1.5) (table
1) [1-3]. 
We also found a positive association between
common NOD2 variant and cancers of the colon (late-
onset, OR=2.2), breast (early-onset breast cancer
OR=1.9 and ductal breast cancer with an in situ
component OR=2.1) and ovary (table 2) [4-7]. 
Positive associations with CHEK2 protein-truncating
alleles were seen for cancers of the thyroid (OR=4.9),
breast (OR=2.2) and prostate (OR=2.2). The missense
variant I157T was associated with an increased risk of
breast cancer (OR=1.4), colon cancer (OR=2.0),
kidney cancer (OR=2.1), prostate cancer (OR=1.7)
and thyroid cancer (OR=1.9) (table 3) [8].
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Table 1. Association between A148T variants and selected types of cancer
A148T  OR 95% Confidence Interval p (adjusted p)
total controls (n=3000) 105 (3.5%) G/A
bladder (n=223) 0 (0%) A/A 7 (3.1%) G/A 0.9 0.4105-1.945 0.7764  (n.s)
colon (n=724) 0 (0%) A/A 37 (5.1%) G/A 1.5 1.012-2.180 0.0423  (0.5499)
stomach (n=246) 0 (0%) A/A 8 (3.3%) G/A 0.9 0.4461-1.925 0.8384  (n.s)
larynx (n=396) 0 (0%) A/A 17 (4.3%) G/A 1.2 0.7326-2.088 0.4255  (n.s)
ovary (n=340) 0 (0%) A/A 12 (3.5%) G/A 1.0 0.5491-1.853 0.9777  (n.s)
lung (n=497) 0 (0%) A/A 34 (6.8%) G/A 2.0 1.358-3.018 0.0004  (0.0052)
prostate (n=348) 0 (0%) A/A 13 (3.7%) G/A 1.1 0.5946-1.925 0.8215  (n.s)
kidney (n=264) 0 (0%) A/A 6 (2.3%) G/A 0.6 0.2788-1.474 0.2915  (n.s)
thyroid (n=173) 0 (0%) A/A 3 (1.7%) G/A 0.5 0.1528-1.549 0.2129  (n.s)
non-Hodgkin
Lymphoma (n=162) 0 (0%) A/A 6 (3.7%) G/A 1.1 0.4585-2.453 0.8909  (n.s)
breast (under 50y)
(n=3318) 0 (0%) A/A 168 (5.1%) G/A 1.5 1.2764-1.832  0.002
melanoma (n=471) 0 (0%) A/A 33 (7%) G/A 2.1 1.387-3.111 0.0003 
pancreas (n=210) 0 (0%) A/A 8 (3.8%) G/A 1.1 0.5246-2.273 0.8140  (n.s)
Table 2. Association of the NOD2 3020insC mutation and selected types of cancer
Site Number tested Number positive Prevalence of 3020ins C (%) Odds ratio p-value
bladder 172 18 10.5 1.5 0.13
breast 462 37 8.0 1.1 0.62
with DCIS 126 18 14.3 2.1 0.009
without DCIS 336 19 5.7 0.76 0.30
colon 255 31 12.2 1.8 0.01
kidney 245 8 3.2 0.4 0.02
larynx 223 23 10.3 1.5 0.11
lung 258 30 11.6 1.7 0.03
melanoma 198 10 5.1 0.7 0.31
ovary 317 35 11.0 1.6 0.03
pancreas 127 6 4.7 0.6 0.37
prostate 298 17 5.7 0.76 0.40
stomach 213 20 9.4 1.3 0.27
thyroid 82 8 9.8 1.4 0.39
controls 1910 140 7.3
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Conclusions
It seems that CDKN2A, NOD2 and CHEK2 are
responsible for a wide range of cancer types.
We estimate that the mutations mentioned above
are responsible for around 20% of malignancies
occurring in the Polish population. According to our
studies over 4 million people in Poland carry one of
the mutations described above. We elaborated genetic
tests for CDKN2A, NOD2 and CHEK2 aimed at
reliable identification of persons with increased risk of
developing cancers of the breast, ovary, lung, prostate,
thyroid, colon, kidney and malignant melanoma.
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Table 3. Association between CHEK2 variants and selected types of cancer
Site No. tested Number positive  (prevalence), odds ratio,  p-value
IVS2 + 1G>A 1100delC Any truncating mutation I157T
bladder 172 1 (0.6%) 1 (0.6%) 12 (7.0%)
OR 1.2    p=0.7 0 OR 0.8    p=0.8 OR 1.5   p=0.3
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controls 4000 19 (0.475%) 10 (0.25%) 29 (0.725%) 193 (4.825%)
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